Objective: To determine whether ␤-amyloid (A␤) peptides segregated into distinct biochemical compartments would differentially correlate with clinical severity of Alzheimer disease (AD).
A CRITICAL ROLE OF THE
␤-amyloid (A␤) peptide in the pathogenesis of Alzheimer disease (AD) has been supported by human, animal, and in vitro studies. 1 Most measures of A␤ are markedly elevated in the AD-affected brain, yet the extent of total A␤ accumulation tends to correlate poorly with AD severity. [2] [3] [4] Because there is evidence that specific biochemical forms of A␤ (eg, A␤ 42 , soluble A␤, and oligomeric A␤) selectively lead to neuronal dysfunction and neurodegeneration [5] [6] [7] and can be more reliable correlates of clinical status, 8, 9 identificationandreliablemeasurementofthesetoxic A␤speciesshouldenhancetheirutilityasbio-logical markers of disease.
Clarifying the dynamics of A␤ production and compartmentalization is also necessary to explain AD pathogenesis. Specific A␤ species may preferentially exert toxic effects as a function of their cellular location. Although established histologic techniques identify primarily insoluble extracellular and vascular amyloid deposits, novel methods can enhance detection of intraneuronal A␤, distinguish A␤ pools, and measure changes in A␤ concentration and location over time. [10] [11] [12] [13] [14] The A␤in the brain can be segregated into distinct biochemical compartments defined by sequential extraction procedures. In this study of brain autopsy samples from a wellcharacterized longitudinal cohort of patients with AD and matched controls, we quantified A␤ 40 and A␤ 42 in biochemical compartments defined by their solubility in 4 solutions. Proteins in these biochemical pools are predicted to derive from distinct anatomical compartmentswithinthecerebralcortex:ex-tracellular soluble, intracellular, membrane associated, and extracellular insoluble. 7 We hypothesized that these measures would differentially correlate with disease diagnosis, progression, and severity.
METHODS

STUDY PARTICIPANTS
The sample derives from the Predictors Study, 15 which consists of patients with AD recruited at the mild to moderate disease stage and examined every 6 months at 1 of 3 academic centers. The inclusion and exclusion criteria and examination procedures have been fully described elsewhere 15 and were approved by the respective institutional review boards. At entry, all patients met National Institute of Neurological and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association criteria for probable AD and had a modified Mini-Mental State Examination (mMMSE) score of 30 or higher (equivalent to Ն16 on the Folstein MMSE). Twenty-seven cases with autopsyconfirmed AD were included in the present study. Thirteen brains of individuals of similar age and sex who were free of neurodegenerative disease by clinical or pathologic criteria were selected as controls.
BIOCHEMICAL COMPARTMENTALIZATION
At autopsy, coronal sections from 1 hemisphere and hemibrainstem were fresh frozen between dry ice-cooled aluminum plates. A 1-cm strip of cortex was dissected from frozen temporal neocortex and cingulate cortex and mechanically homogenized. A 4-step extraction was used. 13 The tissue was first extracted in 14-µL/mg wet weight TRIS buffer, pH 7.2 (50mM TRIS, 200mM sodium chloride, 2mM EDTA, and complete protease inhibitors), with 2% protease-free bovine serum albumin. After centrifugation (15 000 rpm, 21 000g, 4°C, 5 minutes), the supernatant was retained as the TRIS-soluble fraction. The pellet was rehomogenized with TRIS extraction buffer that contained 0.1% Triton X-100 and spun (15 000 rpm, 21 000g, 4°C, 5 minutes), and the supernatant was retained as the Tritonsoluble fraction. The remaining pellet was homogenized in 2% sodium dodecyl sulfate (SDS) and spun, and the supernatant was saved as the SDS-soluble fraction. The remaining pellet was homogenized in 70% formic acid (FA) and recentrifuged (22 000 rpm, 44 000g, 4°C, 5 minutes), and the resulting FA-extracted supernatant was neutralized with 1M TRIS buffer (pH 11.0), representing the FA-extracted fraction.
These fractions are defined by their biochemical properties; however, they are predicted to contain proteins from distinct cellular compartments: extracellular soluble (TRIS), intracellular soluble (Triton), membrane-associated (SDS), and insoluble (FA) proteins. Lesné et al 7 demonstrated that the TRIS fraction was enriched for the extracellular proteins ␣-secretase cleavage product of the amyloid precursor protein and tissue plasminogen activator; the Triton fraction was enriched for intracellular proteins c-jun, tau, extracellular signal-regulated kinases, and jun amino-terminal kinase; and the SDS fraction was enriched for full-length amyloid precursor protein and N-methyl-D-aspartate receptor subunit NR2, suggesting a membrane pro- tein-enriched fraction. The FA fraction contained flotillin-2, suggesting that lipid raft domains and the insoluble proteins may be enriched in that fraction. Although the fractions are enriched for proteins from specific cellular compartments, they are unlikely to correspond precisely to these cellular compartments, and A␤ may spill over between biochemical and cellular compartments during the extraction procedure.
A␤ QUANTIFICATION
Levels of A␤ 40 and A␤ 42 in each fraction were determined by sandwich enzyme-linked immunosorbent assay (ELISA) using capture antibody BNT77 (anti-A␤ [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ) and detector antibodies BA27 (anti-A␤ 40 ) and BC05 (anti-A␤ 42 ), according to published protocols. 13, 16 Thus, using 2 brain regions, 4 biochemical fractions, and 2 ELISAs, 16 A␤ variables were generated for each study participant.
CLINICAL MEASURES
Cognition was assessed using the mMMSE. 17 Modifications to the Folstein MMSE 18 include the addition of digit span forward and backward, 19 2 calculation items, recall of recent US presidents, 10 items from the Boston Naming Test, 20 1 sentence to repeat, 1 written command, and 2 figures to copy. The mMMSE has a maximum of 57 points, with lower scores indicating poorer cognitive function. We used the Blessed Dementia Rating Scale parts I and II to assess patients' functional capacity. This is a 17-point scale, with higher scores indicating worse functional status. 21 Illness duration is the sum of the neurologist's estimate of duration of symptoms at intake and the time from study entry to death.
STATISTICAL ANALYSIS
Cases and controls were compared for group differences in demographics. The means of the 16 A␤ variables were then compared in the 2 groups using t tests. Our approach to limiting the liabilities associated with multiple comparisons included applying a P value of .01 to identify A␤ variables that reliably differed between cases and controls. The 10 variables that met this criterion are included in subsequent analyses. This approach also addressed the conceptual difficulty of interpreting the significance of an amyloid-related measure that is purported to relate to clinical features of AD but does not significantly differ from controls.
The A␤ variables were then compared in AD cases with 0, 1, or 2 APOE-ε4 alleles using 1-way analysis of variance and a post hoc least significant difference. For cross-sectional analysis, linear regression was used to relate the A␤ measures and clinical features of the AD cases. After log transformation of the data to better approximate normal distributions, the results of the analyses were essentially unchanged; we present the untransformed data.
Rates of cognitive decline were compared in groups of AD cases dichotomized at the median of each of the A␤ measures. Because we were interested in declines in mMMSE scores, which eventuated in high or low A␤ levels at autopsy, the time scale was reversed. Thus, date of death is defined as time 0, and preceding examinations have positive time values. Analyses of the longitudinal data were performed by applying the method of generalized estimating equations (GEE) 22 ; GEE takes into account that each individual's multiple mMMSE measurements are likely to be correlated. In our model, time, A␤ level (high or low), and the time ϫ A␤ interaction were included as independent variables. The mMMSE score was the dependent variable. As a result, all study participants had positive regression coefficients for the time; this finding corresponds to a decrease in cognition in chronological time, with higher coefficients indicating more rapid decline. A significant time ϫ A␤ interaction term indicates a differential rate of decline in individuals with high or low A␤ fractions measured at autopsy. The cross-sectional and longitudinal analyses were performed again with sex and age at death included as covariates. The findings were nearly identical; the unadjusted analyses are presented.
RESULTS
Clinical features of the 27 patients with autopsyconfirmed AD are summarized in Table 1 . There were 5 male and 8 female control patients with a mean (SD) age at death of 70.1 (16.2) years; neither of these measures differed significantly from the patients with AD.
CASES vs CONTROLS
Mean A␤ 42 and A␤ 40 levels in the biochemical compartments of temporal and cingulate neocortex are given in Table 2 . Compared with controls, AD-affected brains had significantly higher mean concentrations of A␤ 42 in the TRIS and FA fractions of the temporal and cingulate cortex (PϽ.001) and higher mean concentrations of TRIS and FA A␤ 40 in the temporal (P = .01) and cingulate (P=.03) cortex. Mean Triton and SDS A␤ 42 fractions were higher in the AD temporal and cingulate cortex (PϽ.01). However, mean Triton and SDS A␤ 40 levels were similar in AD and control brains.
APOE-4 GENOTYPE
Of the 27 patients with AD, 14 were heterozygous and 4 were homozygous for the APOE-ε4 allele. Individuals with 0, 1, or 2 APOE-ε4 alleles differed in FA A␤ 40 (P=.001) and TRIS A␤ 40 (P=.01) levels in the temporal cortex. Post hoc analysis revealed that these differences were most pronounced in the 4 APOE-ε4 homozygotes (Figure 1 ). Homozygotes had greater temporal FA A␤ 40 and TRIS A␤ 40 when compared with either heterozygotes (P=.03) or noncarriers (PϽ .01). Mean values were greater in the heterozygotes than noncarriers, but this finding did not reach statistical significance (P = .16). No significant difference was found among the APOE-ε4 groups in Triton A␤ 40 , SDS A␤ 40 , or A␤ 42 levels within any biochemical compartment in either brain region. Table 3 , significant correlations were observed between the last measured Blessed Dementia Rating Scale score and Triton A␤ 42 (r = 0.48, P =.02) and SDS A␤ 42 (r=0.44, P = .03) levels in the temporal cortex after adjusting for time from last assessment until death (ie, worse terminal functional status was associated with higher A␤ 42 levels in the fractions predicted to contain intracellular and membrane-associated proteins). The unadjusted scatterplots are shown in Figure 2 .
CORRELATIONS WITH CLINICAL SEVERITY
As indicated in
ILLNESS DURATION
Significant correlations were observed between illness duration and FA A␤ 40 level (r=0.51, P=.007) and TRIS A␤ 40 level (r=0.57, P = .002) in the temporal cortex. No significant correlation was observed between illness duration and any A␤ 42 measurement. No significant correlation was found between illness duration and age at onset, age at death, or functional impairment at last examination (data not shown).
RATE OF COGNITIVE DECLINE
GEE was used to compare rates of cognitive decline in groups split at the median of measured A␤ at death; results are given in Table 3 and Figure 3 . The mean (SD) number of cognitive assessments was 7.6(4.6) per study participant. An elevated SDS A␤ 42 level in the temporal neocortex was associated with more rapid decline (PϽ .001). In the cingulate cortex, however, higher FA A␤ 42 and SDS A␤ 42 levels were related to slower decline (P=.02 and P=.01, respectively).
COMMENT
In this clinicopathologic correlation study, we observed that all TRIS-and FA-extracted A␤ isoforms were elevated in patients with AD compared with controls; these fractions are predicted to contain extracellular soluble A␤ (TRIS) and insoluble A␤ associated with parenchymal and vascular amyloid deposition (FA). In contrast, in the biochemical compartments predicted to contain intracellular (Triton) and membrane-associated (SDS) protein pools, the A␤ 42 but not the A␤ 40 level was elevated in the patients with AD. These findings are con- Abbreviations: DRS, Dementia Rating Scale; FA, formic acid; NA, not applicable; SDS, sodium dodecyl sulfate. a All analyses reflect unadjusted models using raw data, except for the Blessed DRS correlations, which include time from last examination until death as a covariate. Values are r for the Blessed DRS score and illness duration, F for APOE-ε, and ␤ for the rate of cognitive decline. The reported ␤ in the generalized estimating equation analysis is that of the time ϫ A␤ interaction term; positive values indicate a more rapid cognitive decline for patients with measured A␤ in the upper median. Statistically significant case-control differences (P Ͻ .05) are set in boldface type.
sistent with previous work that established that a range of extracellular A␤ measurements are elevated in the ADaffected brain. Our data suggest that intracellular and membrane-associated A␤ 42 levels may be more closely related to the expression of symptoms in AD than other measured A␤ species.
Among AD cases, we found that only Triton-and SDSextracted A␤ 42 in temporal neocortex correlated with dementia severity at the last examination before death. These measures are predicted to be enriched with intracellular and membrane-associated A␤ 42 . This finding lends support to the contention that accumulation of intracellular A␤ is not simply a marker of disease state but progresses with clinical severity.
In our longitudinal analyses, elevated SDS A␤ 42 levels in the temporal cortex at autopsy were associated with a more rapid cognitive decline observed during the mild to moderate stages of dementia. This finding was of greatest magnitude and statistical significance and supports the contention that A␤ 42 accumulation in the membraneassociated intracellular compartments is closely tied to disease symptoms, such as cognitive changes early in the clinical course.
APOE-ε4 is a well-recognized genetic risk factor for AD, which is associated with younger age at symptom onset. In our study, there was an APOE-ε4 allele doserelated increase in A␤ 40 in the TRIS and FA fractions. This finding is in agreement with previous findings 23, 24 ; the pronounced increase among APOE-ε4 homozygotes was previously reported using methods similar to the current study. 25 Although the molecular mechanism of the APOE-ε4 effect is uncertain, as a genetic factor it likely exerts its influence for years before symptom emergence. Furthermore, we also found TRIS-and FAextracted A␤ 40 to be the strongest correlate of illness duration in our study. Thus, constitutive extracellular A␤ 40 accumulation may be a trait of individuals destined to develop AD. Although their levels appear to increase as a function of genetic risk and illness duration in AD, we could not relate these A␤ 40 species to the clinical state of our study participants. It has been shown that mice that produce only A␤ 40 do not produce cerebral amyloid deposits. 26 Thus, additional factors, including A␤ 42 production, appear necessary to generate toxic amyloid and clinical manifestation of disease.
Recent work has led to increased recognition of the presence and importance of intraneuronal A␤. These studies 27 were enabled by the development of antibodies that could differentiate A␤ 40 and A␤ 42 from the transmembrane amyloid precursor protein from which they derive. In human and mouse brain studies, [28] [29] [30] intraneuronal A␤ has been detected before the emergence of extracellular plaques. In a recent animal study, 31 appearance of intraneuronal A␤ coincided with the emergence of cognitive impairment, which was reversible with immunotherapy. Oligomerization of A␤ associated with increased neurotoxicity has been identified within neurons. Although the sources of intraneuronal A␤ are not well defined, accumulation is known to occur at subcellular compartments of the endosomal pathway 30, 34 and is associated with impairment of intracellular protein trafficking after endocytosis. 35 Recently, genetic studies 36, 37 have also implicated alterations of intraneuronal protein recycling and sorting mechanisms in the pathogenesis of AD. Elsewhere, it has been hypothesized that endocytosed A␤ 42 is not degraded as efficiently as A␤ 40 . 38 The results of the present study support a selective accrual of intraneuronal A␤ 42 with progression of AD. Additional work is necessary to elaborate the mechanisms of extracellular A␤ 40 accumulation and their relation to the protein misprocessing that leads to intracellular A␤ 42 accumulation. A potential link can be sought at the retromer complex, which shuttles proteins from the endosomal system to the secretory pathway. Selective retention of A␤ 42 in the endosomal organelles and/or facilitated transfer of A␤ 40 to the secretory system could account for such findings.
In the longitudinal analysis, results from the cingulate cortex appear discrepant with those of the temporal cortex. We have focused on the temporal cortex data in the figures and discussion for several reasons. Temporal association cortex is more likely to be involved in our patients who were recruited at early stages. Beyond this, the factors that contribute to differential regional vulnerability and alternate patterns of disease progression in AD are poorly understood. Thus, different results by region can be expected and informative. As such, we caution against modeling the whole brain as a homogenous biochemical compartment. In fact, future studies using serial extraction procedures on multiple brain regions may be suitable for analyzing regional covariance in toxic A␤.
A major contribution of the present analyses lies in the careful diagnosis and clinical follow-up that patients received. Clinical diagnosis took place via consensus conference in university hospitals with specific expertise in dementia. The patients were observed prospectively, which eliminates the potential biases of retrospective medical record reviews. Examinations were performed semiannually and included assessments closely proximate to death. Finally, the novelty of the A␤ measures is a significant strength. We are not aware of other studies of human AD-affected brain that include biochemical pools predicted to contain intracellular and membrane-associated proteins.
Relative weaknesses of our study include the limited number of patients studied, which resulted in reduced statistical power; however, multiple data points per patient increased the power of our longitudinal analysis. We do not have detailed clinical information on the control subjects, who were not part of the predictors cohort. However, the control data were used only for between-group comparison and were not included in our cross-sectional or longitudinal analyses of AD patients. We recognize the exploratory nature of the investigation and the problems associated with multiple comparisons. We have attempted to mitigate these by only including in subsequent analyses A␤ variables that, in the initial casecontrol comparison, satisfied a moderately conservative correction for multiple comparisons. Nevertheless, the reported findings should be considered hypothesis generating and require replication and refinement in future studies. In addition, it is likely that our A␤ ELISA is insensitive to certain biologically relevant species of cerebral amyloid. 39 For example, it is expected to quantify monomers only and does not distinguish multimeric forms or N-terminal modifications of the A␤ peptide.
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